Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Accounts Payables (2016 - 2026)

Avanos Medical's Accounts Payables history spans 13 years, with the latest figure at $55.5 million for Q4 2025.

  • On a quarterly basis, Accounts Payables rose 2.21% to $55.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $55.5 million, a 2.21% increase, with the full-year FY2025 number at $55.5 million, up 2.21% from a year prior.
  • Accounts Payables hit $55.5 million in Q4 2025 for Avanos Medical, up from $54.2 million in the prior quarter.
  • Over the last five years, Accounts Payables for AVNS hit a ceiling of $67.9 million in Q4 2022 and a floor of $46.0 million in Q1 2025.
  • Historically, Accounts Payables has averaged $57.5 million across 5 years, with a median of $56.4 million in 2021.
  • Biggest five-year swings in Accounts Payables: fell 27.67% in 2021 and later rose 20.39% in 2022.
  • Tracing AVNS's Accounts Payables over 5 years: stood at $56.4 million in 2021, then rose by 20.39% to $67.9 million in 2022, then fell by 17.08% to $56.3 million in 2023, then dropped by 3.55% to $54.3 million in 2024, then grew by 2.21% to $55.5 million in 2025.
  • Business Quant data shows Accounts Payables for AVNS at $55.5 million in Q4 2025, $54.2 million in Q3 2025, and $48.8 million in Q2 2025.